日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Attributes and Health Care Resource Utilization of Patients on Enzalutamide or Abiraterone for Metastatic Castration-Resistant Cancer in England

英格兰接受恩扎卢胺或阿比特龙治疗的转移性去势抵抗性癌症患者的特征和医疗资源利用情况

期刊:Jco Oncology Practice
影响因子:4.6
doi:10.1200/OP-24-01045
Bahl, Amit; Faria, Rita; Merseburger, Axel S; Attard, Gert; Snijder, Robert; Sodatonou, Hanna; Stark, Sari; Pranzo, Alessandra; Martins, Karla; Rozario, Nigel; Ridsdale-Smith, Jess; Chilelli, Andrew
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study

重新定义瑞戈非尼和三氟尿苷/替吡嘧啶在不联合贝伐珠单抗治疗难治性转移性结直肠癌中的应用：ReTrITA 研究的发现

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17122037
Signorelli, Carlo; Calegari, Maria Alessandra; Anghelone, Annunziato; Passardi, Alessandro; Gallio, Chiara; Bittoni, Alessandro; Lucchetti, Jessica; Angotti, Lorenzo; Di Giacomo, Emanuela; Zurlo, Ina Valeria; Morelli, Cristina; Dell'Aquila, Emanuela; Artemi, Adele; Gemma, Donatello; Emiliani, Alessandra; Ribelli, Marta; Corsi, Domenico Cristiano; Arrivi, Giulia; Mazzuca, Federica; Zoratto, Federica; Chilelli, Mario Giovanni; Schirripa, Marta; Schietroma, Francesco; Morandi, Maria Grazia; Santamaria, Fiorenza; Dettori, Manuela; Cosimati, Antonella; Saltarelli, Rosa; Minelli, Alessandro; Lucci-Cordisco, Emanuela; Basso, Michele
肠癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study

瑞戈非尼剂量递增与固定剂量治疗难治性转移性结直肠癌的真实世界证据：ReTrITA 研究结果

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17203316
Signorelli, Carlo; Basso, Michele; Calegari, Maria Alessandra; Anghelone, Annunziato; Passardi, Alessandro; Gallio, Chiara; Bittoni, Alessandro; Lucchetti, Jessica; Angotti, Lorenzo; Di Giacomo, Emanuela; Zurlo, Ina Valeria; Morelli, Cristina; Dell'Aquila, Emanuela; Artemi, Adele; Gemma, Donatello; Emiliani, Alessandra; Ribelli, Marta; Corsi, Domenico Cristiano; Arrivi, Giulia; Mazzuca, Federica; Zoratto, Federica; Schirripa, Marta; Schietroma, Francesco; Morandi, Maria Grazia; Santamaria, Fiorenza; Dettori, Manuela; Cosimati, Antonella; Saltarelli, Rosa; Minelli, Alessandro; Lucci-Cordisco, Emanuela; Chilelli, Mario Giovanni
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study

德国一项AVENGER研究比较了阿比特龙与恩扎卢胺在未经化疗的转移性去势抵抗性前列腺癌患者中的心血管风险和生存率。

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03132-8
Merseburger, Axel S; Dornstauder, Eugen; Ohlmann, Carsten-Henning; Aprikian, Armen; Junker, Sophia; Hahn, Philipp; Chilelli, Andrew; Stoelzel, Matthias; Serikoff, Alexis; Spitzer, Stefan G
肿瘤
肿瘤免疫
ENG
前列腺癌
AVEN
发表日期：2025
文献求助 收藏

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings

一项荟萃分析旨在评估恩扎卢胺和醋酸阿比特龙在真实世界环境下一线治疗转移性去势抵抗性前列腺癌的相对疗效

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1491314
Aprikian, Armen; Bahl, Amit; Omlin, Aurelius; Baciarello, Giulia; Chakravarty, Abhiroop; Kondaparthi, Prashanth; Gourgioti, Georgia; McLean, Thomas; Serikoff, Alexis; Chilelli, Andrew
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysis

比较高危生化复发性激素敏感性前列腺癌全身治疗的安全性和有效性：一项网络荟萃分析

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1638405
Aprikian, Armen; Chilelli, Andrew; McLean, Thomas; Nasr, Anchen; Ganguli, Arijit; Serikoff, Alexis; Guzman, Franco; Barouma, Ifigeneia; Zacharioudaki, Maria; Freedland, Stephen J
肿瘤
前列腺癌
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study

在转移性去势抵抗性前列腺癌患者中，与恩扎卢胺相比，醋酸阿比特龙与主要心血管事件的关联性：EVADE 研究的事后分析

期刊:World Journal of Urology
影响因子:2.9
doi:10.1007/s00345-025-05841-9
Bahl, Amit; Chilelli, Andrew; Faria, Rita; Rozario, Nigel; Snijder, Robert; Stark, Sari; Merseburger, Axel S
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar's Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

回复 Parth Aphale、Shashank Dokania 和 Himanshu Shekhar 致编辑的信，内容关于 Bahl A、Chilelli A、Faria R 等人发表的题为“转移性去势抵抗性前列腺癌患者中，醋酸阿比特龙与恩扎卢胺相比，主要心血管事件的关联性：EVADE 研究的事后分析”的文章。该文章发表于《世界泌尿外科杂志》43:465。https://doi.org/10.1007/s00345-025-05841-9

期刊:World Journal of Urology
影响因子:2.9
doi:10.1007/s00345-025-06100-7
Bahl, Amit; Chilelli, Andrew; Faria, Rita; Rozario, Nigel; Snijder, Robert; Stark, Sari; Merseburger, Axel S
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Methodological approach to optimize a step-by-step deterministic linkage of SNDS data with a clinical database (FREGAT) of gastric/gastroesophageal junction adenocarcinoma in France: Pitfalls and learnings

法国胃/胃食管交界处腺癌临床数据库（FREGAT）与SNDS数据逐步确定性链接的方法优化：陷阱与经验教训

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0333667
Laborey, Magali; Lajoinie, Audrey; Freilich, Jonatan; Samalin, Emmanuelle; Bouché, Olivier; Piessen, Guillaume; Stoelzel, Matthias; Chilelli, Andrew
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada

转移性去势敏感性前列腺癌强化治疗：一项在加拿大阿尔伯塔省开展的真实世界研究

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2479374
Yip, Steven M; Cheung, Winson Y; Aprikian, Armen; Stoelzel, Matthias; Wong, Kelvin; Pranzo, Alessandra; McLean, Thomas; O'Sullivan, Dylan E; Chilelli, Andrew
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏